C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer

World Journal of Gastroenterology

Volumn 10, Issue 8, 2004, Pages 1115-1120

  Ilhan, Nevin ^a   Ilhan, Necip ^a   Ilhan, Yavuz ^a   Akbulut, Handan ^a   Küçüksu, Mehmet ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; MALONALDEHYDE; NITRIC OXIDE; PROCALCITONIN; VASCULOTROPIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; GASTROINTESTINAL INFECTION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MALE; METABOLITE; OXIDATIVE STRESS; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

EID: 2342440884     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i8.1115     Document Type: Article

References (61)

1. Wu CW, Li AF, Chi CW, Huang CJ, Huang CL, Lui WY, Lin WC. Arg tyrosine kinase expression in human gastric adenocarcinoma is associated with vessel invasion. Anticancer Res 2003; 23: 205-210
2. Zivny J, Wang TC, Yantiss R, Kim KH, Houghton J. Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol 2003; 36: 50-60
3. Shukla NK, Deo SV, Asthana S, Raina V, Dronamaraju SS. Neoadjuvant chemotherapy in advanced gastric cancerresults of a pilot study. Trop Gastroenterol 2002; 23: 94-96
4. Chatelain D, de Lajarte Thirouard AS, Tiret E, Flejou JF. Adenocarcinoma of the upper esophagus arising in heterotopic gastric mucosa: common pathogenesis with Barrett's adenocarcinoma? Virchows Arch 2002; 441: 406-411
5. Ohno S, Fujii T, Ueda S, Nakamoto T, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Kumar Dhar D, Nagasue N. Predictive factors and timing for liver recurrence after curative resection of gastric carcinoma. Am J Surg 2003; 185: 258-263
6. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Engl J Med 1995; 333: 1757-1763
7. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149-4156
8. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233-235
9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
10. Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1994; 14: 385-394
11. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, Sasaki T. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829
12. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000; 128: 408-416
13. Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbeck's Arch Surg 1999; 384: 264-270
14. Ferrara N, DavisSmyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25
15. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359: 843-845
16. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, Yamamoto H. Possible participation of autocrine and paracrine vascular endothelial growth factor in hypoxiainduced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270: 28316-28324
17. Waltenberger J, Mayer U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647-1652
18. Gulumian M. The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol Cell Biochem 1999; 196: 69-77
19. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. N Engl J Med 1990; 323: 1228-1233
20. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 1986; 8: 1-27
21. Kramer BS, Johnson KA. Other gastrointestinal cancers: stomach, liver. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer Prevention and Control. New York: Marcel Dekker 1995: 673-694
22. O'Connor F, Buckley M, O'Morain C. Helicobacter pylori: the cancer link. J R Soc Med 1996; 88: 674-678
23. Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull 1998; 54: 139-150
24. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001; 22: 1947-1953
25. Cahill RJ, Kilgallen C, Beattie S, Hamilton H, O'Morain C. Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. Gut 1996; 38: 177-181
26. Blaser MJ, Parsonnet J. Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest 1994; 94: 4-8
27. Forman D. Helicobacter pylori infection and cancer. Br Med Bull 1998; 54: 71-78
28. Correa P, Miller MJ. Carcinogenesis, apoptosis and cell proliferation. Br Med Bull 1998; 54: 151-162
29. Arii K, Tanimura H, Iwahashi M, Tsunoda T, Tani M, Noguchi K, Mizobata S, Hotta T, Nakamori M, Yamaue H. Neutrophil functions and cytokine production in patients with gastric cancer. Hepatogastroenterology 2000; 47: 291-297
30. Rossi G, Fortuna D, Pancotto L, Renzoni G, Taccini E, Ghiara P, Rappuoli R, Giudice G. Immunohistochemical study of lymphocyte populations infiltrating the gastric mucosa of beagle dogs experimentally infected with Helicobacter pylori. Infect Immun 2000; 68: 4769-4772
31. Tanahashi T, Kita M, Kodama T, Yamaoka Y, Sawai N, Ohno T, Mitsufuji S, Wei YP, Kashima K, Imanishi J. Cytokine expression and production by purified Helicobacter pylori urease in human gastric epithelial cells. Infect Immun 2000; 68: 664-671
32. Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E. Expression of interleukin6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 1997; 88: 953-958
33. Kabir S, Daar GA. Serum levels of interleukin1, interleukin6 and tumour necrosis factoralpha in patients with gastric carcinoma. Cancer Lett 1995; 95: 207-212
34. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European J Cancer 2003; 39: 184-191
35. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131
36. Hahm KB, Lee KJ, Choi SY, Kim JH, Cho SW, Yim H, Park SJ, Chung MH. Possibility of chemoprevention by the eradication of Helicobacter pylori: oxidative DNA damage and apoptosis in H pylori infection. Am J Gastroenterol 1997; 92: 1853-1857
37. Farinati F, Cardin R, Degan P, Rugge M, Mario FD, Bonvicini P, Naccarato R. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut 1998; 42: 351-356
38. Brozozowski T, Konturek SJ, Sliwowski Z, Drozdowicz D, Zaczec M, Kedra D. Role of Larginine, a substrate for nitric oxidesynthase, in gastroprotection and ulcer healing. J Gastroenterol 1997; 32: 442-452
39. Kato S, Kitamura M, Korolkiewicz RP, Takeuchi K. Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and synthase inhibitor. Br J Pharmacol 1998; 123: 839-846
40. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: lessons from human tumours. Cancer Metastasis Rev 1998; 17: 107-118
41. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19: 711-721
42. Kallio R, Surcel HM, Bloigu A, Syrjala H. Creactive protein, procalcitonin and interleukin8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000; 36: 889-894
43. Karzai W, Oberhoffer M, MeierHellmann A, Reinhart K. Procalcitonin - a new indicator of the systemic response to severe infection. Infection 1997; 25: 329-334
44. Gabay C, Kusner I. Acute phase protein and other systemic responses to inflammation. N Engl J Med 1999; 6: 448-454
45. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acutephase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastases in broad spectrum neoplastic diseases. Scand J Immunol 1984; 19: 193-198
46. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours, 5th ed. International Union Against Cancer. In: Wittekind CH, ed. New York: Wiley-Liss 1997: 59-62
47. Yagi K. Assay of blood plasma or serum. Met Enzymol 1984; 105; 328-331
48. 15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
49. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme' D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14: 263-277
50. Watanabe A, Maehara Y, Okuyama T, Kakeji Y, Korenaga D, Sugimachi K. Gastric carcinoma with pyloric stenosis. Surgery 1998; 12: 330-334
51. Wu CW, Wang SR, Chao MF, Wu TC. Serum Interleukin6 levels reflect disease status of gastric cancer. Am J Gastroentrol 1996; 91: 1417-1422
52. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545
53. Salgado R, Vermeulen PB, Benoy I, Weyjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892-897
54. Salgado R, Benoy I, Weytjens R, Vermeulen PB, Dirix LY. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients - reply. Br J Cancer 2000; 82: 1896
55. Zhang GJ, Adachi I. Serum interleukin6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-1432
56. Everett SM, Singh R, Leuratti C, White KL, Neville P, Greenwood D, Marnett LJ, Schorah CJ, Forman D, Shuker D, Axon AT. A Levels of Malondialdehyde-Deoxyguanosine in the Gastric mucosa: relationship with lipid peroxidation, ascorbic acid, and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev 2001; 10: 369-376
57. Assreuy J, Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol 1993; 108: 833-837
58. DeRojas-Walker T, Tamir S, Ji H, Wishnok JS, Tannenbaum SR. Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chem Res Toxicol 1995; 8: 473-477
59. Xiao L, Eneroth PH, Qureshi GA. Nitric oxide synthase pathway may mediate human natural killer cell cytotoxicity. Scand J Immunol 1995; 42: 505-511
60. Mordan LJ, Brunett TS, Zhang LX, Tom J, Cooney RV. Inhibitors of endogenous nitrogen oxide formation block the promotion of neoplastic transformation in C3H 10T1/2 fibroblasts. Carcinogenesis 1993; 14: 1555-1559
61. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by Creactive protein. Cytokine 1992; 4: 361-368